427 related articles for article (PubMed ID: 37144580)
1. Smart drug delivery systems to overcome drug resistance in cancer immunotherapy.
Yi W; Yan D; Wang D; Li Y
Cancer Biol Med; 2023 May; 20(4):248-67. PubMed ID: 37144580
[TBL] [Abstract][Full Text] [Related]
2. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
Zhou L; Zhang P; Wang H; Wang D; Li Y
Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
[TBL] [Abstract][Full Text] [Related]
3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
[TBL] [Abstract][Full Text] [Related]
5. Nanoengineered drug delivery in cancer immunotherapy for overcoming immunosuppressive tumor microenvironment.
Park SH; Eun R; Heo J; Lim YT
Drug Deliv Transl Res; 2023 Jul; 13(7):2015-2031. PubMed ID: 36581707
[TBL] [Abstract][Full Text] [Related]
6. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
7. Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy.
Yan WL; Lang TQ; Yuan WH; Yin Q; Li YP
Acta Pharmacol Sin; 2022 Dec; 43(12):3045-3054. PubMed ID: 36050519
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
9. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
10. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis.
Zhu L; Wu J; Gao H; Wang T; Xiao G; Hu C; Lin Q; Zhou Q
Chin Med J (Engl); 2023 Dec; 136(23):2787-2801. PubMed ID: 37442772
[TBL] [Abstract][Full Text] [Related]
11. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
[TBL] [Abstract][Full Text] [Related]
12. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review.
Hossen S; Hossain MK; Basher MK; Mia MNH; Rahman MT; Uddin MJ
J Adv Res; 2019 Jan; 15():1-18. PubMed ID: 30581608
[TBL] [Abstract][Full Text] [Related]
13. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
14. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
15. Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.
Fakhri S; Moradi SZ; Faraji F; Farhadi T; Hesami O; Iranpanah A; Webber K; Bishayee A
Cancer Metastasis Rev; 2023 Sep; 42(3):959-1020. PubMed ID: 37505336
[TBL] [Abstract][Full Text] [Related]
16. A Hierarchical Structured Fiber Device Remodeling the Acidic Tumor Microenvironment for Enhanced Cancer Immunotherapy.
Li Y; Yuan R; Luo Y; Guo X; Yang G; Li X; Zhou S
Adv Mater; 2023 May; 35(21):e2300216. PubMed ID: 36912443
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.
Nel AE; Mei KC; Liao YP; Liu X
ACS Nano; 2022 Apr; 16(4):5184-5232. PubMed ID: 35348320
[TBL] [Abstract][Full Text] [Related]
18. Application of nanotechnology in circumventing immunotolerance.
Ma Y; Shen Y; Zhu B; Li D; Liu J
Pharmazie; 2020 Oct; 75(10):470-477. PubMed ID: 33305719
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.
Li Z; Lai X; Fu S; Ren L; Cai H; Zhang H; Gu Z; Ma X; Luo K
Adv Sci (Weinh); 2022 Aug; 9(22):e2201734. PubMed ID: 35652198
[TBL] [Abstract][Full Text] [Related]
20. Bioengineered nanogels for cancer immunotherapy.
Ma X; Li SJ; Liu Y; Zhang T; Xue P; Kang Y; Sun ZJ; Xu Z
Chem Soc Rev; 2022 Jun; 51(12):5136-5174. PubMed ID: 35666131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
